Ionis Pharma (IONS): Rasio kapitalisasi pasar marang pendapatan
Ionis Pharmaceuticals (IONS) relies on its own R&D centers while utilizing the capacity of contract manufacturing plants. Revenues are generated through royalties and licensing agreements with pharmaceutical behemoths. High-margin RNA therapy effectively blocks the synthesis of harmful proteins in genetic pathologies. The current status is 4.70, which is clearly demonstrated by the price-to-sales ratio chart.
Rincian analitis perusahaan Ionis Pharma (IONS)
- nilai saham lan prakiraan konsensus rega:
- data kapitalisasi bursa:
- indikator kapitalisasi buku:
- indikator beban kredit lan likuiditas emiten:
Rasio Total Utang marang Ekuitas Ionis Pharmaceuticals|IONS - Utang jangka dawa marang modal|Kewajiban jangka cendhak marang modal Isis Pharmaceuticals|IONS - Gunggung utang perusahaan|Utang-utang marang kapitalisasi buku Ionis Pharma|IONS - Kewajiban jangka dawa perusahaan|Gedhene kewajiban jangka cendhak Ionis|Koefisien jangkoan perantara ionispharma.com
- data bathi bisnis lan rasio investasi:
IONS - Bathi resik|Bathi mangsa ngarep Ionis Pharmaceuticals|IONS - Pangali P/E|Pangali Forward P/E Ionis Pharmaceuticals, Inc.|IONS - Rasio rega marang bathi tumrap wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Ionis Pharma|IONS - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi resik saben saham sajrone patang kuartal pungkasan Ionis|IONS - Bathi resik saben saham (EPS TTM)|Owah-owahan bathi resik saben saham taun-ka-taun sajrone rolas wulan pungkasan ionispharma.com|IONS - Wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham ing taun ngarep Ionis Pharmaceuticals
- rincian pendapatan lan dodolan emiten:
Ringkesan analitik perusahaan:IONS ionispharma.com
For Ionis Pharmaceuticals (IONS), whose business is based on scalable RNA therapeutics, this indicator reflects market expectations for the future monetization of patented developments relative to current revenues. By analyzing the price-to-sales ratio on the GURU.Markets platform, an investor assesses the extent of the premium paid for growth potential, comparing market capitalization with actual revenue to identify the gap between the speculative price and fundamental cash flows.
Karo sapa Ionis Pharmaceuticals saingan
Multiplikator P/S Tempus AI (TEM)|Rasio rega marang pendapatan Qiagen QGEN|Rasio kapitalisasi pasar marang pendapatan RGEN|RNA - Rasio rega marang pendapatan|CRISPR (CRSP) - Kapitalisasi marang pendapatan|WGS: Multiplikator P/S|ultragenyx.com (RARE) - Multiplikator P/S|BEAM (Beam Therapeutics) - Multiplikator P/S|Kapitalisasi marang pendapatan Sarepta Therapeutics (SRPT)|Multiplikator P/S TWST|TXG - Rega marang dodolan|Intellia Therapeutics - Kapitalisasi marang pendapatan|Multiplikator P/S stoketherapeutics.com STOK|BLFS: Kapitalisasi marang pendapatan|Wave Life Sciences Ltd - Kapitalisasi marang volume dodolan|MAZE: Multiplikator P/S|SION - Koefisien rega marang pendapatan|PRME (Prime Medicine, Inc.) - Multiplikator P/S|Kapitalisasi marang pendapatan tayshagtx.com (TSHA)|Multiplikator P/S QURE|Multiplikator P/S MeiraGTx Holdings (MGTX)|Rasio rega marang pendapatan Regenxbio RGNX|Solid Corp - Rasio rega marang pendapatan|OCGN - Rasio rega marang pendapatan|Koefisien rega marang pendapatan pacb.com PACB|BNTC: Multiplikator P/S|DSGN - Koefisien rega marang pendapatan|Rasio rega marang pendapatan Rocket Pharmaceuticals Inc|Rega marang dodolan 4D Molecular Corp FDMT|Rasio rega marang pendapatan Lexeo Therapeutics (LXEO)|korrobio.com - Rasio kapitalisasi marang pendapatan|Rasio rega marang pendapatan Editas Medicine EDIT|Koefisien rega marang pendapatan Silence Therapeutics PLC (SLN)|ProQR Therapeutics NV - Multiplikator P/S|CDXS (Codexis, Inc.) - Rasio kapitalisasi marang pendapatan|Sangamo Therapeutics (SGMO) - Rasio rega marang pendapatan|Rasio kapitalisasi marang pendapatan NAUT|MGX (Metagenomi) - Multiplikator P/S|Multiplikator P/S precisionbiosciences.com|Multiplikator P/S GBIO|Koefisien rega marang pendapatan Boundless Bio Inc|Rasio rega marang pendapatan Exicure XCUR|Imunon Inc (IMNN) - Rega marang dodolan|PHIO - Rasio rega marang pendapatan|MBIO (Mustang Bio, Inc.) - Rasio kapitalisasi marang pendapatan|RNAZ: Multiplikator P/S|BNGO - Koefisien rega marang pendapatan|Rasio rega marang pendapatan Applied DNA Sciences|bluebirdbio.com (BLUE) - Koefisien rega marang pendapatan|Kapitalisasi marang pendapatan IPA (ImmunoPrecise Antibodies)|OMGA (Omega Therapeutics Inc) - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Singular Genomics Systems Inc OMIC|RGLS (Regulus) - Rasio rega marang dodolan|Syros Pharmaceuticals - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan TBIO (telesisbio.com)|TCON: Multiplikator P/S|Unity Biotechnology Inc. (UBX) - Multiplikator P/S
